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Interest in the cardioprotective effects of long chain omega-3 polyunsaturated fatty acids (LCn3) was largely
inﬂuenced by the low rates of cardiovascular disease (CVD) amongst the Inuits of Greenlandwho consumed a
high marine fat diet rich in LCn3s. This ﬁnding stimulated years of epidemiological and clinical studies
investigating the cardioprotective effects of LCn3s, thought to be primarily mediated through anti-
inﬂammatory (and anti-aggregatory) prostaglandins that protect the vascular wall from pro-inﬂammatory
effects of metabolic stress precipitated by poor diet and lifestyle. Although the original hypothesis of the
link between LCn3s and CVD protectionwas based on a high LCn3 containing diet (namely a highmarine fat
diet) the majority of clinical trials since have focussed on EPA and DHA supplementation, and results of
repeated meta-analyses have not shown conclusive evidence in support of their beneﬁcial health effects. In
this review we focus on the controversies that surround the efﬁcacy of LCn3s in cardiovascular and other
chronic diseases and present emerging areas of research for novel applications.Wewill examine factors that
can impacton theefﬁcacyof LCn3s suchas source (plant vsmarinevs supplements (algal vsmarine)), stability
of product, dose, trial duration, ratio of EPA:DHA, and ratio of LCn6:LCn3 fatty acids in the diet.
© 2016 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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Research on the beneﬁcial aspect of LCn3s was prompted by the
remarkably low rate of cardiovascular disease (CVD) amongst the
Inuits of Greenland. A series of studies conducted on Inuits showed
that despite consuming a high marine fat diet, the people had
extremely low levels of Coronary Heart Disease (CHD) [1]. Inter-
estingly, diabetes was essentially unknown in the population as
compared to the Danish population living in Denmark [2]. The In-
uits exhibited lower serum LDL-cholesterol and triglycerides,
higher HDL-cholesterol and higher levels of LCn3 eicosapentaenoic
acid (EPA) to LCn6 arachidonic acid (AA), compared to their Danish
counterparts. Since this observation, a large number of experi-
mental and clinical studies have demonstrated the health beneﬁts
of long chain n-3 PUFAs, however not all studies have been
consistent. Bang and colleagues [3] hypothesised that eicosa-
pentanoic acid (EPA) plays a crucial role in lowering the incidence
of atherosclerosis, coronary heart disease and diabetes. In partic-
ular, the presence of EPA in the walls of the blood vessels instead of
AAwas reported to create an anti-thrombotic state that lowered the
incidence of coronary heart disease amongst the Inuits [2]. This
work has since been supported by a substantial body of evidence. In
addition to this, researchers demonstrated that prostaglandins
derived from LCn6 had increased pro-inﬂammatory activity
compared with those derived from LCn3. Furthermore, studies
suggested that EPA and docosohexanoic acid (DHA) derived from
LCn3 are structurally and functionally distinct from the prosta-
glandins that are derived from AA. Marine plants and ﬁsh are the
twomain sources of dietary LCn3 [4]. Themost concentrated source
of LCn3 comes from fatty ﬁsh such as salmon, tuna and mackerel.
LCn3s are incorporated into the cell membrane, thereby modu-
lating cellular signalling, gene expression and membrane protein
function. Dietary supplementation of LCn3 is known to promote
secretion of anti-inﬂammatory prostaglandins and decrease leu-
kotrienes [5]. These anti-inﬂammatory properties are thought to be
beneﬁcial in cardiovascular diseases and metabolic syndrome dis-
orders such as central obesity, insulin resistance, hypertension and
dyslipidemia [6,7]. Over the last decade, an increasing amount of
experimental evidence suggests a crucial role played by DHA on
neurodegenerative conditions such as mild cognitive impairment
(MCI) [8,9] and Alzheimer's Disease [10].
While most epidemiological evidence and randomized control
trials (RCTs) indicate the protective role of LCn3 on general health
and wellbeing, there are some RCTs that have shown no effect [11].
The aims of this review are to evaluate (a) the evidence of the
beneﬁcial effects of LCn3 on various disease conditions such as
metabolic syndrome and cardiovascular disease (b) discuss why
some RCTs may not have positive outcomes, (c) highlight contro-
versies in LCn3 efﬁcacy and (d) identify emerging areas for LCn3
application as therapeutic agents.
2. Source of LCn3s: diet versus supplementation
Since the initial interest sparked by the Inuit studies, there has
been a vast amount of research into the area of dietary ﬁsh intake,
LCn3 supplementation and disease prevention and treatment.
Controversy exists, however, as to whether LCn3 intake is respon-
sible for beneﬁts seen, whether ﬁsh intake itself is beneﬁcial, or if
ﬁsh intake is merely a marker for a healthier dietary pattern. The
evidence for diet versus supplementation in different disease states
should be considered and will be reviewed in this article.
(i) Diet versus supplementation - CVD events
Epidemiological support for the protective effect of ﬁsh isillustrated by the concept of the blue zone diets. So-called ‘blue
zones’ are areas of the world where populations experience
longevity (>100 years of age or more) and reduced morbidity
compared to other populations [12]. Notable blue zone areas
include the islands of Ikaria and Sardinia in the Mediterranean and
Okinawa in Japan, with these areas having a high dietary intake of
LCn3 amongst other dietary patterns. Fish is the major source of
LCn3 intake in Japan and there are many examples of epidemio-
logical support for a high LCn3 intake from ﬁsh, such as the Nurse's
Health Study and the Chicago Western Electric Study which
demonstrated an inverse relationship between ﬁsh consumption
and mortality, particularly from CVD events [13e15]. Paradoxically,
some epidemiological studies, show no relationship between LCn3
intake from ﬁsh and mortality [16] or that ﬁsh consumption is only
protective in high risk groups [17].
Following on from the ‘blue zone’ diet concept there was in-
terest in the use of supplemental LCn3 in cardiovascular disease,
with signiﬁcant reductions reported for secondary prevention of
myocardial infarction [18]. Additionally, the Diet and Reinfarction
Trial (DART) is an example of an RCT demonstrating that both ﬁsh
consumption and dietary LCn3 supplementation could reduce
mortality in the 2 years post-myocardial infarction [19]. Another
study by Brazionis and colleagues [20], however, showed that ﬁsh
consumption rather than ﬁsh oil improved risk factors of CVD such
as blood pressure and waist to hip ratio. Controversy also exists in
regards to how different CVD risk factors are impacted by ﬁsh oils.
There is evidence supporting dietary supplementation with LCn3
ﬁsh oil in management of high triglycerides with meta-analyses
showing a positive beneﬁt on triglycerides with dietary supple-
mentation [21], with certain populations receiving themost beneﬁt
including those with chronic renal disease or HIV positive pop-
ulations receiving Highly Active Antiretroviral Therapy (HAART)
[22]. A recent meta-analysis by Wei and Jacobson [23] compared
the effects of supplementation of DHA and EHA concluding that
both DHA and EPA lower triglycerides, with divergent effects on
LDL and HDL cholesterol. Cardioprotective dietary patterns such as
a Mediterranean style diet or a ‘blue zones’ type eating pattern
include a wide variety of plant foods consumed with high levels of
antioxidants and other bioactive nutrients that may act in a pro-
tective and synergistic way, increasing the quality of fatty acids
incorporated into tissues.
(ii) Diet versus supplementation - Cognitive function
The role of LCn3 have also been examined in relation to cogni-
tive function. Once again the current evidence suggest that certain
populations may beneﬁt more than others and different LCn3 may
be important. A prospective cohort study by Morris and colleagues
[24] demonstrated an inverse relationship between DHA and total
LCn3 intake in older people, with no protective effect seen with
EPA. Intervention trials have so far failed to support a role for
supplementation to improve cognitive function in those with Alz-
heimer's Dementia [25] and with mixed results reported in healthy
individuals [26,27]. A possible theory behind the conﬂicting and
lack of positive results of supplement trials is the oxidisable nature
of ﬁsh oil supplements which may reduce the bioavailability.
(iii) Diet versus supplementation - Fatty liver disease
An example illustrating the complexity of this research area is in
fatty liver disease studies. A recent meta-analysis by Parker et al.
[28] examined the role of LCn3 supplementation in reducing liver
size. This was stimulated by previous research that showed patients
with Non-Alcoholic Fatty Liver Disease (NAFLD) had habitually low
consumption of ﬁsh compared to individuals without NAFLD
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tation with LCn3 may be helpful in reducing liver fat, however it
was noted by the authors that some studies included in the meta-
analysis included concurrent dietary modiﬁcation which may have
potentially confounded the results [28]. Challenges in study design
and assessment of habitual LCn3 consumption are also echoed by
Issa and colleagues [31] in their recent meta-analysis examining
the effect of LCn3 intake on cognitive function.
The question remains, is it more than the LCn3 content of ﬁsh
that has a role to play in both the secondary and primary preven-
tion of disease? Are other nutrients present in ﬁsh important, or are
dietary patterns associated with a high ﬁsh intake higher in other
protective nutrients as well?
(iv) Variety is key
An extension of this idea is that a wide variety of LCn3 sources
may be an important factor in disease prevention. Simopoulos [32]
asserts that some Mediterranean diets, namely the traditional
Greek diet, have high omega-3 intake from both animal sources
(ﬁsh, seafood and eggs) as well as from plants (namely leafy greens
such as purslane and legumes). Fish contains other potentially
important nutrients such as taurine, selenium and astaxanthin
which may displace less healthy components of the diet. Other
traditional diets high in LCn3 have also been shown to be effective
in both the primary and secondary prevention of CVD. The Medi-
terranean diet is high in LCn3 content and traditional dietary pat-
terns in Japan are also associated with a lower rate of CVD, with
average n-3 PUFA intake of 1e2 g/day, which is 3e4 times the
intake of most Western populations [33]. Notably, both dietary
patterns have a high intake of plant based food including fruits,
vegetables and ﬁsh and lower intakes of red or processed meat and
reﬁned grains, and have LCn3 from a variety of sources.
A study examining the Seventh Day Adventist Population in
North America, notably another blue zone and long-living popu-
lation, concluded that nut intake may be protective against mor-
tality [16]. Nuts, such as walnuts, are a high dietary source of LCn3s
namely alpha linolenic acid. A more recent European study, the
PREDIMED trial, showed that a Mediterranean diet supplemented
with nuts (walnuts, almonds and hazelnuts) increased protection
against metabolic syndrome [34]. This study examined the effects
in older adults, a high risk population, once again suggesting that
different interventions may be suitable or more effective in
different populations. Another meta-analysis by Pan et al. sug-
gested high intakes of ALA were associated with lower CVD events
[35]. The dietary strategy of increased ALA consumption is
appealing, as plant sources of LCn3 are more accessible and
affordable for the majority of the population. However, the con-
version from ALA to EPA is limited (approximately 8% in men and
9% in women) and conversion to DHA can be very low (reports of
<0$1% in men and 9% in women) [36] and so the main sources of
long chain are marine-based.
(v) Evolving dietary habits
A further area of complexity and controversy relates to the po-
tential decline of dietary LCn3 that coincides with an increase in
urbanisation and afﬂuence in a population. Red meat consumption
generally increases with afﬂuence and can contribute signiﬁcantly
to the ratio of LCn3:LCn6 in the human diet. A recent study by Daley
and colleagues [37] showed grass fed beef contained up to ﬁve
times higher levels of LCn3 than grain fed beef. Furthermore, game
meats such as deer and kangaroo, although low in total fat, have
proportionally high levels of LCn3 derived from their diet of wild
edible plants rich in ALA [38]. Therefore, as suggested by Howe andcolleagues [35], the source of redmeat and productionmethods are
important considerations, as these factors impact the fatty acid
composition of the meat.
With a shift towards a Western dietary pattern that occurs with
increased afﬂuence there is a corresponding decrease in protein
sources that are high in LCn3 such as offal and brain. Consumption
of higher fat protein sources would improve the LCn3 to LCn6 ratio
and it is this that may be key when it comes to disease prevention
and treatment as discussed elsewhere in this article. Similarly,
when ﬁsh intake is examined, some studies demonstrate lower
levels of LCn3 in farmed ﬁsh [39] whereas others claim that the
total fat content of farmed ﬁsh is higher. For example, Cahu and
colleagues [40] suggest that while the proportion of EPA and DHA
in farmed ﬁsh is low compared to wild ﬁsh, when expressed as a
proportion of total fat, the total amount in grams is higher. These
authors also noted that ﬁsh feed has an inﬂuence on the fatty acid
proﬁle. The cooking method utilised can also alter the fatty acid
composition with methods such as deep frying changing the fatty
acid proﬁle [41]. Some studies show reduced cardiac beneﬁts with
fried ﬁsh and ﬁsh sandwiches compared to grilled or baked ﬁsh
[42]. In a recent meta-analysis, Li [43] suggests that the variability
in the type of ﬁsh consumed, total LCn3 intake and cookingmethod
may a possible reason for conﬂicting results in epidemiological
studies.
Lifestyle and dietary changes are notoriously hard to achieve
and maintain, and may potentially be environmentally unsustain-
able, whereas compliance with dietary supplements may be easier
and more accessible for some individuals. Furthermore, the sus-
tainability of ﬁsh oil supplements, which deplete our reserves of
oily ﬁsh, needs to be considered. The emerging use of algal oils in
LCn3 supplementation offers a lot of promise. Although the ﬁnd-
ings of trials examining singular nutrients have yielded mixed re-
sults, it is apparent that some population groups beneﬁt more than
others and ongoing research is justiﬁed [44].
3. Importance of the dietary LCn6:LCn3 fatty acid ratio and
controversies surrounding the role of fatty acids in CVD
Modulating dietary fat continues to be the mainstay of treat-
ment for cardiovascular disease and non-communicable chronic
diseases generally [45]. However, recent meta-analyses have chal-
lenged our understanding of the role of fatty acids in CVD risk,
concluding that apart from trans fats that are positively associated
with CVD risk, the evidence for an association between all other
fatty acids (selected saturated fats, monounsaturated fats and
polyunsaturated fats (LCn6 and LCn3)) and CVD risk is not strong or
is inconclusive [46]. It has been argued however, that the lack of
conclusive evidence linking fatty acids to CVD risk may be due to
the poor quality of published trials including self-reported mea-
surement of fatty acid intakes, variations in trial length and mea-
surement of biomarkers of fatty acids and genetic variation in trial
participants affecting response to interventions [42,46]. Another
issue is trials including LCn6 and LCn3s together yet they have
distinctively different and opposing properties [47,48]. Although
there is general consensus for the need to replace trans fats and
saturated fats with healthier fats such as monounsaturated and
polyunsaturated fats, there is emerging evidence that excess con-
sumption of n-6 polyunsaturated fatty acids (beyond 10% of energy
intake) may increase CVD risk by increasing oxidation of LDL
cholesterol, and increased vasospasm, vasoconstriction and
increased platelet aggregation [49]. Recent studies have high-
lighted the importance of the LCn6/LCn3 ratio in CVD risk, rather
than the amount of individual fatty acids [49].
The two essential fatty acids in the diet that cannot be syn-
thesised internally are linoleic acid (or omega-6; C18:2n-6; LNA)
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precursor of arachidonic acid, which in turn is a precursor for a
variety of vasoconstrictive, pro-inﬂammatory and pro-aggregatory
molecules that are important in the body's response to inﬂamma-
tion. ALA is a precursor of both eicosapentanoic acid (C20:5n-3;
EPA) and docosahexanoic acid (C22:6n-3; DHA), which have
important anti-inﬂammatory [50] vasodilator and anti-aggregatory
functions [51]. The LCn6 and LCn3 fatty acids therefore have
opposing effects which highlights the importance of an appropriate
n-6 to n-3 fatty acid ratio. As argued by Simopoulos [32], the ratio of
LCn6:LCn3 fatty acids in the diet has rapidly increased to about 20:1
with industrialisation and westernization of society and a move
away from traditional diets such as the traditional archetypal
Mediterranean diet of the 1950s. The diets of paleolithic man,
which were rich in plant foods and wild animals, were reported to
have an LCn6 to LCn3 ratio of close to unity [32]. The traditional
Greek-style Mediterranean diet is reported to have a LCn6:LCn3
ratio of 2:1 due to high plant sources of ALA, high EPA and DHA
from ﬁsh and other seafoods, and consumption of free range eggs,
chickens and meat (goat and lamb) that graze on a high ALA diet
from wild edible plants and herbs, snails and worms [32].
In our experience it is difﬁcult to achieve a low LCn6:LCn3 ratio
with the current Westernised food supply with its abundance of
processed foods, intensively reared animal foods and vegetable
cultivars that are low in LCn3s [52]. Careful planning is required to
select free range produce, oils and nuts rich in LCn3s, oily ﬁsh and
seafoods rich in LCn3, and breads and cereals that are supple-
mented with LCn3s.4. LCn3s action in biological systems
(i) Metabolic syndrome
Metabolic syndrome is a constellation of risk factors for car-
diovascular disease and diabetes which includes obesity, insulin
resistance, hypertension and dyslipidaemia [44]. It is commonly
suggested that metabolic abnormalities, including metabolic syn-
drome, increase with the level of obesity. When nutrient intake
exceeds the metabolic demands of the body, the excess energy is
stored as triglyceride in various tissues of the body including
skeletal muscle, adipocytes and liver. The adipocytokines released
by adipose tissue regulate various functions including inﬂamma-
tion and also components of the metabolic syndrome [53].
Inﬂammation appears to play a central role in the pathophysiology
of metabolic syndrome and it is known to act mainly through an
initiation phase. During the initiation phase, the LCn6 arachidonic
acid (AA) is released, which is converted to pro-inﬂammatory ei-
cosanoids such as prostaglandin (PGE2), thromboxane, 5-lip-
oxygenase and leukotriene [50]. These pro-inﬂammatory
leukotrienes and eicosanoids activate NF-Kb, which is a crucial
mediator of inﬂammation and regulates more than 200 genes
involved in pro-inﬂammatory cascades and apoptosis. The resolu-
tion of inﬂammation in metabolic syndrome is achieved by a trans-
cellular processes that use the LCn3s EPA and DHA to synthesize
specialized pro-resolving lipid mediators [6]. These mediators
terminate neutrophil inﬁltration into sites of injury and control
neutrophil apoptosis and the clearance of apoptotic neutrophils by
macrophages, thereby returning inﬂamed tissue to a state of ho-
meostasis [6]. While it is a concern that metabolic syndrome is a
growing pandemic worldwide, dietary modiﬁcations and physical
activity have been suggested to tackle this issue to reduce one or
more risk factors for metabolic syndrome [19].
(ii) Cardiovascular diseaseCardiovascular disease is major cause of mortality worldwide
due to the underlying multifactorial causes. Several key studies
have examined diet-derived LCn3 and health interactions. The Diet
and Reinfarction study (DART) study includedmen recovering from
myocardial infarction who were given dietary advice including
consumption of at least two weekly portions of fatty ﬁsh. Menwho
complied with this dietary advice had a 29% reduction in mortality
compared withmenwho did not receive this dietary advice [19,54].
In addition, the Oslo study, which was a 5 year observational study,
also showed that dietary changes and smoking cessation resulted in
a lower incidence of coronary events [55]. While there are
numerous data suggesting the cardioprotective effects of LCn3s,
emerging reports call for a careful consideration on the age, gender
and pathophysiology of the CVD factors which could potentially
affect the metabolism of LCn3s. One study showed that after acute
EPA supplementation, males exhibited a reduction in both platelet
aggregation and microparticle activity, whereas females showed
signiﬁcantly reduced platelet aggregation but not microparticle
activity after DHA supplementation only [56].
LCn3 supplementation has also been shown to have car-
dioprotective effects in patients with coronary heart disease. A
meta-analysis which included fourteen RCTs showing a reduction
on LCn3 supplementation from 3 months to more than 1 year
duration, indicated that supplementation decreased the risk of
death due to all causes and also from sudden cardiac death [57]. In
addition to these RCTs showing a reduction in CVD events and
death due to all causes, there are reported beneﬁts among patients
without documented CVD as well [58,59]. One of the potential
causes of ﬁnding no effect in other studies could be attributed to a
low dose of LCn3 (<1 g), since the therapeutic dosage for hyper-
triglyceridemia is ~4 g/day and signiﬁcant variations in study
design, including differences in baseline levels of LCn3, duration of
supplementation and inadequate study power [60]. Also, whilst
positive beneﬁts for LCn3 supplementation in addition to standard
therapy in heart failure have been reported [22], medications used
in CVD treatment may also compromise potential beneﬁts of LCn3
supplementation, as shown in the instance of statin prescribed
patients [61]. Further studies with higher doses of LCn3 are
required in CVD patients, as well patients without documented
CVD, with the monitoring of co-prescriptions so that this therapy
can be uniformly recommended in primary prevention patients.
5. Controversies in LCn3 efﬁcacy
(i) Stability of LCn3 supplements
There are LCn3 supplement intervention studies that, despite
very similar intervention design and patient population, have quite
different outcomes [62,63]. One of the possible reasons for in-
consistencies in the reported beneﬁts of LCn3 supplementation
may be due to the instability of fats contained within LCn3 sup-
plements. A recent study by Albert and colleagues [64] investi-
gating the fatty acid quality and content of ﬁsh oil supplements,
measured oxidation markers and the EPA and DHA concentrations
of 32 supplements available in New Zealand. The majority of the
products analysed exceeded the recommended indices of oxidative
markers, with only 8% meeting the recommendations. Peroxide
values (PV) and anisidine values (AV) were measured, allowing for
calculation of total oxidation (Totox). However, at a recent meeting
of experts in Geelong, Australia (December 2015), the validity of the
analyses in the Albert et al. [64] paper were questioned and
considered ﬂawed as similar analyses conducted by the Common-
wealth Scientiﬁc and Industrial Research Organisation (CSIRO) of a
similar range of ﬁsh oil capsules demonstrated good compliance
with the label claims and oxidation of these lipids was not
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non-standard techniques in their analyses.
Furthermore, another study investigating 11 LCn3 products for
persistent organic pollutant proﬁles reported that products
adhered closely to manufacturer speciﬁcations and met chemical
guideline thresholds [66]. The variation in ﬁndings, when inde-
pendently analysing products, raises another issue of consistent
methodologies used in analyses of LCn3 stability. Whilst measures
of oxidation should be reported for baseline and post-intervention
supplements in future ﬁsh-oil studies to identify quality of fatty
acids throughout intervention, validated methods should be used
to avoid inconsistencies of results.
The quality of fats contained within an LCn3 products can be
impacted by heat and light conditions of the environment in which
they are stored in, factors that cannot be controlled for in a free
living intervention study. Moreover, even in a controlled environ-
ment, foods enriched with LCn3 show an increase in peroxide
values over time [67]. Most LCn3 intervention studies that have
been published do not report oxidation analytics of supplemental
products used within the intervention. Analytical data should be
reported on products used within clinical trials at baseline and at
end point, to identify any compromise of fatty acid quality which
may have occurred throughout the study. These analytical assess-
ments of the supplement quality at end point may be conducted on
excess capsules returned at the cessation of the intervention.
Analytical reports should include concentrations of EPA and DHA
fatty acids and oxidation indices including PV, AV and Totox using
validated analytical methodologies. The addition of antioxidants to
LCn3 enriched products can improve oxidative stability of fatty
acids [67] and studies that have reported different ﬁndings despite
similarities of LCn3 intervention design may have different out-
comes dependent on the longevity of the product quality. An
example of the possible impact of antioxidants added to LCn3
supplements on outcome, is the reported beneﬁts in implantable
cardioverter deﬁbrillator (ICD) patients and outcomes of ventricu-
lar tachycardia or ventricular ﬁbrillation in a study that used an
LCn3 supplement containing added antioxidants [63], in compari-
son to a study reporting no ventricular tachycardia or ventricular
ﬁbrillation beneﬁts in ICD patients using an LCn3 supplement not
reported to contain added antioxidants [62].
Given the possibility of oxidation affecting the beneﬁts of LCn3
supplements, considerations should be made in intervention
studies to use a supplement which contains added antioxidants or
even the use of LCn3 supplement sources that are naturally rich in
antioxidants. Consideration for supplementation using LCn3 sour-
ces naturally containing greater amounts of antioxidants compared
to shrimp, trout or salmon may include krill oil, rich in the anti-
oxidant astaxanthin, Vitamin A and Vitamin E [68]. Additionally,
krill oil may be more effective compared to ﬁsh oil as a source of
LCn3s due to the phospholipid structure of krill oil. A recent study
showed that krill oil interventionwas more effective than ﬁsh oil in
increasing LCn3, reducing LCn6:LCn3 ratio, and improving the
omega-3 index [69].
(ii) Disparity in reported fatty acid concentration of supplement
Analytical data has shown disparity in the content of DHA and
EPAwithin LCn3 products compared to the reported concentrations
provided by manufacturers on product labels.
In the Albert and colleagues [64] study investigating ﬁsh oil
supplements available in the New Zealand market, it was found
that a number of major suppliers of LCn3 capsules were over-
reporting LCn3 concentration, with supplements containing on
average 68% of the reported EPA and DHA concentrations and some
supplements containing as little as 32% of the EPA and DHAconcentrations reported on the product label. Only three out of 32
analysed supplements had equal or higher quantities of EPA and
DHA than reported on the product label [64]. However, as noted
above, the ﬁndings of the Albert et al. (2015) study have been
disputed by experts at a recent scientiﬁc meeting, due to non-
standard analysis techniques. Alternatively, other studies investi-
gating disparity between product claimed concentrations of fatty
acids and independent analysis showed similar concentrations
between the manufacturer and independent analysis [70].
Whilst analytical methodologies used should be validated and
recognised, it is apparent that reliance on label reported EPA and
DHA values weakens the strength of evidence from LCn3 supple-
ment intervention studies. In the potential instance that previous
studies with no effect from LCn3 intervention used a supplement
that contained much lower quantities of LCn3 than indicated by
manufacturer labelling, this may have affected outcomes of the
study. This supports that future LCn3 supplementation studies
should have independent analytical veriﬁcation, using validated
methods, of capsule fatty acid concentration. These analytical re-
sults should also be reported within publications arising from these
intervention studies. LCn3 content and quality data should be
provided in publications to aid not only quality control of inter-
vention but also determine true intervention dose.
(iii) Omega-3 index levels - Compliance indicators and eligibility
criteria
Studies on LCn3 supplementation commonly report objective
compliance by analysing circulating plasma LCn3 blood levels
before and after the intervention. Plasma LCn3 levels, while good
indicators of acute increase or decrease in fatty acid intake, are not
indicative of sustained intake [71]. Plasma LCn3 levels reﬂect recent
intakes whereas red blood cell LCn3 reﬂects long-term intakes [72].
Reporting erythrocyte LCn3 levels at baseline at post-intervention
would be a more robust method of reporting objective compli-
ance in LCn3 intervention studies. The EPA and DHA concentration
in the erythrocyte membrane constitutes the omega-3 index, and
the omega-3 index has been proposed as a predictor of CVD mor-
tality [73,74]. The omega-3 index has been shown to increase in a
dose-dependent manner with increases in EPA and DHA supple-
mentation [75]. Reporting objective compliance by measuring the
omega-3 index of study population at baseline and post interven-
tion is likely to strengthen consistency of study ﬁndings in the area
of LCn3 interventions.
Some studies which report baseline and post-intervention
circulating LCn3 levels show large variation between baseline
levels within intervention and control groups. As it has been re-
ported that an LCn3 index of ~8% is associated with car-
dioprotection and an index of ~4% associated with the least
protection [73] outcomes of LCn3 intervention are likely to be more
pronounced in the instance of participants beginning with low
omega-3 index levels compared to those beginning with moderate
to high, highlighting the importance for researchers to take into
account baseline LCn3 levels e particularly baseline erythrocyte
LCn3 levels, as this will be a stronger indicator of dietary LCn3
intake 3months prior to participation andmay reduce confounders
to effect size. Within the study design of future LCn3 intervention
trials, including a cut off for baseline LCn3 index levels in the in-
clusion/exclusion criteriamay further strengthen the consistency of
research outcomes. Alternatively, participants with higher omega-3
index baseline levels should be removed from data analysis or re-
sults categorised based on these values.
(iv) Variability in trial methodology e LCn3 dose
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cognitive impairment [76] compared evidence from ﬁve RCTs; four
studies reported consistent improvement in cognition measures
whereas one study, which used a low dose intervention in com-
parison to the other interventions, found no improvement in
cognition [76] (Table 1). These ﬁndings highlight the importance of
dose and for independent assessment of DHA and EPA concentra-
tion of supplement in order to reach an effective dose. Cognitive
functions were evaluated by Kotani et al. [77] before and after 90
days supplementation of 240 mg/day of arachidonic acid and DHA
or 240 mg/day of olive oil (placebo), in both patients with mild
cognitive impairment (MCI) and Alzheimer's disease. There were
no signiﬁcant improvements in either Alzheimer's disease patients
or a placebo group, however patients treated with arachidonic acid
and DHA with MCI showed a signiﬁcant improvement of the im-
mediate and memory score.
Similarly, a 24 week double blinded RCTconducted by Chiu et al.
(2008) detected a signiﬁcant improvement in the cognitive portion
of the Alzheimer’ s Disease Assessment Scale (ADAS-cog) in the
group of participants with MCI who received LCn3 1.8 g/day
compared to the placebo group (p ¼ 0.03) [78]. These results were
not observed in the participants with Alzheimer's disease. As Sinn
et al. (2010) suggest, these results could be indicative that the early
stages of cognitive decline may be optimal for intervention with
LCn3 [79].
As illustrated in Fig. 1, there appears a clear delineation in
beneﬁts of omega-3 for cognition according to dose. Jackson et al.
[80] suggest studies which administer less than 2 g LCn3s per day
are unlikely to produce clinically relevant cognitive performance
enhancements in healthy populations. Whilst larger doses may
appear to illicit stronger outcomes, particularly in cognition,
omega-3 research is complex, with variability in individual baseline
intake and variability in trial methodology (study duration, sup-
plements used, dosage, populations etc.). There may also be a need
for caution in some populations, as indicated by the conﬂicting
results of the DART and DART-2 trials in patients with ischaemic
heart disease. Whilst the DART trial demonstrated a reduction in
all-cause mortality among those taking ﬁsh oil, the DART-2 trial
reported that participants taking ﬁsh oil had a higher risk of cardiac
death [81].Table 1
Summary of DHA/EPA dietary intervention trials in patients with mild cognitive impairm
Ref Clinical trials with MCI patients (n,
mean age)
Dosage of
DHA/EPA per day
Trial dura
[78] Patients with MCI
(23, 74 yrs)
0.72 g DHA þ 1.08 g EPA or
placebo
6 months
double
blinded p
controlled
[77] Patients with MCI
(23, 68 yrs)
240 mg DHA þ 240 mg AA or
placeboo
3 months
Placebo co
[84] Elderly persons with MCI
(36, 66 yrs)
1.3 g DHA þ 0.45 mg of EPA or
placebo
12 month
Randomiz
blinded
placebo c
[85] Elderly patients suffering from MCI.
(11, 85 yrs)
1.4 g DHA þ 572 g EPA or
placebo
3 months
Randomiz
blinded
placebo c
[86] Older people with MCI
(100, 74 yrs)
180 mg DHA þ 120 mg EPA or
placebo
6 months
Randomiz
blinded
placebo c
AA ¼ Arachadonic Acid; DHA ¼ Docosahexaenoic acid; EPA ¼ Eicosapentaenoic acid; M
heimer's Disease Assessment Scale; CIBIC plus ¼ Clinician's Interview-Based Impression
logical Status; RAVLT: Rey's Auditory Verbal Learning Test; CDT ¼ Clock Drawing Test; WRecently conducted RCTs investigating DHA supplementation in
healthy populations detected little or no evidence of cognitive
enhancing effects of 400 mg of DHA supplemented for 25 and 50
days [82] nor with supplementation with 252 mg of DHA, 60 mg of
EPA and 10mg of Vitamin Ewas for 90 days [83]. Plasma DHA levels
and compliance were not reported by Benton et al. [82]; addi-
tionally, a lack of signiﬁcant change in these interventions may be
due to insufﬁcient dose and supplementation period. Stough et al.
[83] reported signiﬁcantly higher plasma DHA levels in the inter-
vention compared to the placebo group post-treatment; this in-
crease did not translate to enhancement of cognitive function.
Investigators speculated that the negative ﬁndings may reﬂect that
the existing diet of participants did not provide sufﬁciently low
levels on LCn3s to permit a beneﬁt from supplementation [82].
(v) Duration of intervention
Results of a recent trial suggest EPA-rich supplementation may
be more beneﬁcial in improving behavioural cognitive outcomes
compared to DHA-rich supplementation in healthy populations.
Bauer et al. [87] compared a high EPA intervention group (400 mg
ﬁsh oil; 3:1 ratio EPA:DHA) and a high DHA intervention group
(365.7 mg ﬁsh oil; 4:1 ratio DHA:EPA) supplemented for 30 days.
Behavioural outcomes were signiﬁcant in the EPA-rich group; re-
action times were decreased compared with supplementation rich
in DHA (p ¼ 0.04) whereas DHA-rich supplementation did not
induce any behavioural improvement. Brain activation changes
were detected in both groups; EPA-rich supplementation produced
a decrease in the functional activation in the anterior cingulate
cortex compared with prior to supplementation. DHA-rich sup-
plementation increased functional activation in the precentral gy-
rus. It was concluded that following the 30-day intervention period
EPA-rich supplementation was more successful than DHA-rich
supplementation in improving neural efﬁciency during higher or-
der cognitive tasks [87].
A Cochrane review [88] of three high quality RCTs found no
beneﬁt to cognitive function from LCn3 supplementation in
cognitively healthy adults over 60 years of age. These authors
identiﬁed length of supplementation as a limitation of the trials;
the shortest trial duration was 26 weeks and the longest was 40ent (MCI) in the last 10 years [76].
tion and design Measures Outcome
Randomized
lacebo-
trials
ADAS-cog; CIBIC - plus Signiﬁcant improvement in
ADAS-cog; in patients with MCI after
omega-3 supplementation
,
ntrolled trial
Japanese version of
RBANS
(5 cognitive domains)
Improvement of immediate memory
and attention in omega-3
supplemented group
s,
ed double
ontrolled trial
RAVLT, MMSE, CDT,
WAIS-R
Signiﬁcant improvement in cognitive
function in omega-3 supplemented
group
,
ed double
ontrolled trial
MMSE Signiﬁcant improvement in MMSE,
semantic verbal ﬂuency and olfactory
sensitivity assessment in omega-3
supplemented group
,
ed double
ontrolled trial
MMSE, AMT Low prescription dose had no effect on
cognitive function in omega-3
supplemented group
MSE ¼ Mini-Mental State Examination; ADAS-cog ¼ cognitive portion of the Alz-
of Change Scale; RBANS ¼ Repeatable Battery for the Assessment of Neuropsycho-
AIS-R ¼Wechsler Adult Intelligence Scale; AMT ¼ Abbreviated Mental Test.
Fig. 1. Effect of LCn3s on cognitive function in cohort and RCT studies by dosage category of LCn3 consumption. Of interest, a number of the studies showing beneﬁts of
omega-3 for cognition (high dose studies) are in elderly populations; whereas a number of the other studies showing no beneﬁts have primarily been conducted in younger
participants. Presumably the elderly cohorts are also at increased risk and therefore more likely to see positive beneﬁt. RCT, randomized control trial; DHA, docosohexanoic acid.
Adapted from http://www.goedomega3.com/index.php/ﬁles/thumb/333/0 [9,77,78,84,91e112].
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cognitive function did not decline in either the placebo or inter-
vention group, indicative that the relatively short intervention
period may have limited capacity to detect potential delays to
cognitive decline. Dosage and supplement formulation were not
discussed as potential limitations of the studies. This is an impor-
tant issue to consider since, as illustrated in Fig. 1, there appears a
clear delineation in beneﬁts of omega-3 for cognition according to
dose.
(vi) Intervention population
In cognitively impaired, but non-demented people, both DHA
and total LCn3s are lower. Low serum DHA level is considered a
signiﬁcant risk factor for the development of Alzheimer's dementia
[90], and thus the population's baseline serum DHA levels may
impact on efﬁcacy of intervention on outcomes. Whilst efﬁcacy of
DHA intervention appears to be stronger in people with low
baseline serum DHA levels, interventions in younger healthy pop-
ulations may help identify the role of LCn3s in longer-term pre-
ventative treatment and progression to a cognitively impaired
phenotype.
Currently, a consensus is yet to be reached as to optimal vari-
ables required to produce cognitive enhancing effects. RCTs have
produced inconsistent results; discrepancies between trials could
partially be attributed to these dose and duration variations of LCn3
and additionally the health status in the populations studied.
Additionally, increasing duration of studies, whilst improving our
understanding of LCn3 supplementation in health outcomes, may
increase participant burden and result in reduced compliance and
increased attrition, hence reducing study quality.(vii) False positive and negative outcomes
Another area of controversy includes the variability of outcome
measure tools used across studies. As an example, contrasting
ﬁndings regarding the effects of omega-3 on cognitive function
may be due to more sensitive outcome tools developed in recent
years. The emergence of computerised battery testing, compared
with traditional paper-based assessments of cognitive function are
generally agreed to reduce the risk of false positive and negative
ﬁndings (Type 1 and Type 2 statistical errors), whichmay have been
more prevalent in earlier studies.
6. Emerging novel concepts for application
(i) LCn3s and mental health
There is an increasing body of evidence suggesting that LCn3s
are important in mental well-being. DHA is a major structural
component of neuronal membranes, and changing the fatty acid
composition of neuronal membranes leads to functional changes in
the activity of receptors and other proteins embedded in the
membrane phospholipid [113]. LCn3s are known to have important
physiological functions that directly acts on neuronal activity.
Studies indicate a strong association between depression and low
dietary intake of LCn3s [114] as well as correlation between rates of
homicide and mental disorders with LCn3 levels [115]. Interest-
ingly, studies show reduced levels of LCn3s in red blood cell
membranes of depressive and schizophrenic patients [114].
Double-blind, placebo-controlled trials in schizophrenia, and trials
in depression, have reported therapeutic beneﬁt from LCn3s, when
given in addition to antidepressant therapy [114,116,117].
At a cellular level, LCn3s are incorporated into all cell
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particularly enriched. Furthermore, these fatty acids perform a
plethora of actions, including facilitating the conformational
changes of rhodopsin, assisting in nerve cell signalling and neuro-
development, modulating the activities of cardiac ion-channel
proteins, and modifying gene expression [113,114,116,117]. At the
molecular level, LCn3s can affect gene and protein expression,
modulate membrane protein activity, and serve as a reservoir for
bioactive molecules. Several mechanisms have been proposed by
which LCn3 acts as an antidepressant, these include (i) regulating
serotonergic and dopaminergic neurotransmitters in signal trans-
duction [118,119], (ii) EPA may have a beneﬁcial effect on
hypothalamic-pituitary-adrenal axis dysfunction, treatment-
resistant depression, and multidrug resistance through the action
of P-glycoprotein, which transports many substrates, including
steroids [115,120], and (iii) LCn3 beneﬁcial effects on depression
andmood could be by interfering with parts of the arachidonic acid
cascade such as inhibitory effect of LCn3 on phospholipase A2
(PLA2) [121,122]. Neuroimaging studies are also being used to help
to evaluate the neurobiological effects of omega-3 inmental health.
For example, a current RCT is assessing the effect of LCn3 treatment
in an older age cohort on depressive symptoms and correlating
these with brain changes [123].
(ii) LCn3s and cognitive function - therapeutic/preventative
Studies in children with attention deﬁcit hyperactivity disorder
(ADHD) or other developmental disorders supplemented with ﬁsh
oil supplements have shown improvements in their learning and
performance at school [124e126]. In older more vulnerable groups,
it also appears that LCn3 may help to improve cognitive function
[76] and to slow conversion from MCI to Alzheimer's disease [127]
In healthy young and older individuals evidence from randomized
clinical trial research had been mixed with regard to seeing a
beneﬁt with cognition. For example, a large trial in 70e80 year olds
in the UK (OPAL; n ¼ 687 participants), supplemented for 2 years
with 700 mg per day of EPA and DHA and powered for cognitive
effects, did not show improvements in cognition [89]. Yurko-Mauro
et al. [9] did show improvements in paired-associates learning
using a sensitive computerised cognitive battery (CANTAB) in 485
individuals supplementing with 900 mg of DHA for 24 weeks. The
choice of cognitive endpoints has also been raised as an issue, with
earlier studies using very course measures of cognition. In more
recent years, computerised cognitive tasks have proven useful for
assessing potential improvements in cognitive faculties that
decline most with age [9,128].
Positive studies have also highlighted the importance of using
an optimal experimental design that includes selection of partici-
pants with low levels of LCn3. Stonehouse et al. [27] selected 176
younger healthy individuals (18e45) with low levels of LCn3 and
found signiﬁcant improvements in cognition following 6 month
supplementation. Similarly, Witte et al. [108] showed in healthy
older individuals (50e75) signiﬁcant improvements in cognition
and brain structure following omega-supplementation. Moreover,
improvements in executive functionwere correlated with increases
in the omega-3 index. Studies which have not selected on the basis
of lower omega-3 status have found negligible cognitive effects in
healthy adults supplemented for 6 months with DHA in an older
cohort aged 50e70 years [129] and in younger adults supple-
mented with EPA or DHA (1 g) for 12 weeks [80]. Interestingly in
the younger adults there was evidence of increases in cerebral
blood ﬂow [80,99].
Other studies using functional neuroimaging found more efﬁ-
cient brain activity in healthy young participants following sup-
plementation with EPA rich supplements as compared to DHA richsupplements [87,130]. Another recent study showing improve-
ments in cardiovascular function and cognition [131] may have
been facilitated by the concurrent supplementation with a multi-
vitamin [132]. The authors suggested that co-factors in the sup-
plement and the diet may be important for the uptake of omega-3
into red cells and therefore important for health endpoints such as
cognition.
(iii) LCn3s and the microbiome
The gut microbiome, its metabolites and the integrity of the gut
wall (intestinal permeability) are emerging as important contrib-
utors to human health and the development of chronic diseases.
Over the last 10 years, there is evidence that chronic diseases may
in fact have infective contributors which are inﬂuenced by the food
we eat [133]. This represents a paradigm shift in our thinking
regarding the cause and treatment of many chronic diseases. On the
one hand, adverse changes to gut microbes have been implicated in
the development of diet-induced obesity [134], chronic inﬂam-
mation [135,136] and insulin resistance [137]. On the other hand,
beneﬁcial changes to gut microbes and their metabolites may
explain the health beneﬁts of the plant-based Mediterranean diet
[138,139].
The discovery that gut dysfunction and elevated serum lipo-
polysaccharides (LPS) from bacterial cell walls were associatedwith
obesity or insulin resistance in mice [135,136,140] and humans
[141,142] provided new insights into a potential linkage between
gut microbes, gut barrier function, white adipose tissue inﬂam-
mation and diet. The human gastrointestinal tract is host to a
complex microbial ecosystem of hundreds of bacterial species also
known as the gut microbiome. A diverse microbiome appears to
play a crucial role in the development of a healthy gut and immune
system, while disturbances (or reduction in diversity) have been
associated with systemic inﬂammation and chronic diseases. Ani-
mal, and a limited number of human, studies have shown that diets
high in animal protein, animal fat and sugar and low in ﬁbre and
unreﬁned carbohydrates are associated with reduced microbiota
diversity, increased relative abundance of undesirable bacteria and
their toxic metabolites, including the cardiotoxin trimethylamine-
N-oxide (TMAO) [143].
Gut microbes are not only inﬂuenced by ﬁbre, resistant starch
and carbohydrates but also by the type and amount of dietary fat,
which, in turn, may directly or indirectly impact the host. Recent rat
studies found that dietary lipids, mainly saturated fats, adversely
affect speciﬁc populations of gut microbes and their metabolic end
products, for example by secreting pro-inﬂammatory products that
impair gut barrier function, leading to systemic endotoxemia and
inﬂammation as well as insulin resistance [144]. These pro-
inﬂammatory products may also enhance energy harvest, leading
to a positive energy balance and obesity. This in turn may further
adversely inﬂuence gut microbes creating self-perpetuating cycles
of gut and systemic dysfunction.
In animal studies, long chain saturated fatty acids may decrease
the abundance of A. muciniphila, a speciﬁc type of mucin-degrading
bacteria that plays a preventative role in the development of diet-
induced obesity. Short chain saturated fatty acids such as those
found in milk fat (and potentially coconut oil) may also preferen-
tially select for mucosal sulfate/sulﬁte-reducing bacteria (i.e.,
B. wadsworthia) that diminish epithelial integrity and increase in-
testinal permeability through their production of the pro-
inﬂammatory and genotoxic gas hydrogen sulﬁde [144]. Surpris-
ingly little has been reported on the effects of LCn3s on gut mi-
crobes. However, consuming diets rich in LCn3 has been reported to
protect intestinal cells from pro-inﬂammatory insults that
contribute to inﬂammatory bowel disease, or activation of immune
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decreasing activation of pro-inﬂammatory MAPKs, NF-kB, activator
protein-1, and (c) increasing PPARg [144].
Dietary LCn3s have been reported to protect intestinal epithelial
cells from pro-inﬂammatory insults and accelerate recovery from
inﬂammation which may reduce intestinal permeability. For
example, EPA and DHA maintained the integrity of human intes-
tinal epithelial cells exposed in-vitro to interleukin-4 (IL-4) by
enhancing epithelial resistance and membrane integrity [145].
Consumption of ﬁsh oil-rich diets containing 25%e30% (w/w) EPA
and DHA or perilla oil containing 55%e60% (w/w) a-linolenic acid
(C18:3n-3) relieved chronic ileitis in senescence-accelerated P1/Yit
mice by inhibiting monocyte recruitment in inﬂamed intestinal
tissue [146]. Supplementation of LCn3s has also been shown to
reduce plasma endotoxin levels in dextran sodium sulfate (DSS)-
induced colitis in rats [147].
In summary, potential mechanisms by which LCn3s protect gut
health include [144]:
(1) reduction of NF-kB-mediated inﬂammation in immune and
intestinal cells. NF-kB signalling is reduced by activation of
peroxisome proliferatoreactivated receptor (PPAR)-g, which
in turn suppresses inﬂammatory gene expression by directly
interfering with transcriptional activation of NF-kB and
activator protein-1.
(2) inhibition of inducible nitric oxide synthase and nitric oxide
production.
(3) anti-inﬂammatory actions through incorporation into the
phospholipid membranes of plasma or immune cells or gut
mucosal tissue as demonstrated in human and rodent
models.
(4) reduced intestinal cytokine production via reduced synthesis
of phospholipids derived from LCn6s, resulting in decreased
production of arachidonic acid and its pro-inﬂammatory,
cyclooxygenase- or lipoxygenase-derived prostaglandins,
thromboxanes and leukotrienes.
Rat studies have also shown that reducing the LCn6:LCn3 ratio
to at least 4.5:1 signiﬁcantly attenuated the abundance of pro-
inﬂammatory thromboxanes and prostaglandins in the colon in
Wistar rats [148]. Having an LCn6 to LCn3 ratio of 3:1 or lower
prevented damage of intestinal mucosal layer and resolved in-
ﬂammatory colitis manifestations in both SpragueeDawley and
Wistar rats [147,148].
Therefore, limiting both saturated and LCn6 fat intake and
increasing sources of LCn3s, ﬁbre and complex carbohydrate-rich
foods as sources of prebiotics should help promote healthy pop-
ulations of gut microbes, thereby improving intestinal health and
reducing the risk of gut and systemic inﬂammation and related
diseases.
(iv) LCn3s in parenteral nutrition and liver disease
There is emerging evidence for the use of LCn3s in speciﬁc
disease states requiring specialized nutrition intervention. Areas of
current research include the use of ﬁsh oils as part of nutrition
support regimens in patients who are admitted to intensive care
units, who require nutrition support following gastrointestinal
surgery and in thosewho are unable tomeet their nutritional needs
through oral diet alone. Liver disease in patients receiving paren-
teral nutrition (PN), nutritional formula infused directly into the
blood stream is well known, particularly in those receiving long
term PN support. Other complications associated with PN include
increased risk of infection, increased ventilator days in critically ill
patients and increased length of stay. The proposed physiologicalmechanisms behind these complications are multifactorial and
beyond the scope of this article, however a key theory behind these
complications is increased inﬂammation driven by the fatty acid
proﬁle. Traditionally, soy bean oil has been the major component of
parenteral lipid solution as it contained sufﬁcient amounts of
essential fatty acids, linoleic acid and a-linolenic acid to prevent
deﬁciency. The predominant fatty acid in soybean oil is however
linoleic acid, resulting in a high and unfavourable LCn6 to LCn3
ratio of 5:1 [149]. Furthermore there is emerging evidence that
intravenous lipid emulsions that include mixed oil sources such as
an olive oil/soy oil blend supplementing PNwith ﬁsh oil may have a
positive impact on PN related liver disease [150] and may have
favourable outcomes such as reduced length of stay [23,151,152].
This remains an emerging area of research with more studies
required to determine the optimal fatty acid proﬁle and which
groups of patients will beneﬁt most.
7. Conclusions
The original focus on LCn3 fatty acids and cardiovascular disease
was prompted by the remarkably low rates of CVD in the native
Intuits of Greenland. These native peoples of Greenland consumed
a high marine fat diet from seals and walruses with a modest
amount of plant foods, yet remained healthy. A plethora of epide-
miological studies have supported the protective effects of a high
ﬁsh diet and reduced CVD and this has been supported by well
controlled clinical trials such as the GISSI-Prevenzione trial. LCn3
supplementation trials have not experienced the same consistency
of ﬁndings for CVD protection, nor in emerging areas of potential
beneﬁts such as reversal of metabolic syndrome and NAFLD,
reversal of early cognitive decline, reversal of depression and the
health of the microbiome. Recent reviews of the efﬁcacy of sup-
plementation trials have highlighted issues with study design such
as inadequate intervention periods, poor sample size of studies,
inadequate dose of supplements, variations in the ratio of EPA to
DHA and issues of supplement quality due to oxidative degrada-
tion. Furthermore, the focus on LCn3 fatty acid dose may not be
hitting the target, as emerging evidence supports a balance of
n6:n3 towards unity in the diet rather than individual dose of LCn3.
It appears that LCn3 supplementation at the appropriate dose, in
the appropriate high risk population group, and for an adequate
durationwill ultimately have a beneﬁcial effect on health especially
in inﬂammatory conditions. Additionally, whilst it appears to be
people with low baseline serum DHA levels, and those at an older
age, that beneﬁt the most, long term interventions in younger
healthy populations will help identify the role of LCn3s in pre-
ventative treatment. However, without a focus on improving the
LCn3 content of the diet and the n6:n3 ratio we are employing a
short term solution for a long term chronic problem.
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